Shire Seizes On Gaucher Opening With EMEA Filing For Velaglucerase
This article was originally published in The Pink Sheet Daily
Given the shortage of Genzyme's Cerezyme treatment, European regulators decided to grant an accelerated review for Shire's medication.
You may also be interested in...
Although the drugs in question all are manufactured or finished and filled at the Allston Landing, Mass., plant, Genzyme says the current difficulty is not related to prior manufacturing problems associated with that facility.
The company showcased its expanded cancer drug pipeline two months after completing the acquisition of Seagen last year.
Biopharma veteran Ted Love assured industry that the sector remains fundamentally strong during remarks at the BIO CEO & Investor Conference.